RECRUITING Phase 3 ClinicalTrials.gov

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

Sponsor: ADARx Pharmaceuticals, Inc. • ClinicalTrials.gov ID: NCT07428499

Registry updated: 2026-09-04

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.

Interventions

ADX-324 Dose Level 1 (Drug)
siRNA duplex oligonucleotide
ADX-324 Dose Level 2 (Drug)
siRNA duplex oligonucleotide

Eligibility criteria

Inclusion Criteria: * Have a documented diagnosis of HAE (Type I or II) * Completed Study ADX-324-301 * Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist) Exclusion Criteria: * A negative reaction to study drug in ADX-324-301

Conditions

Hereditary Angioedema (HAE) Hereditary Angioedema - Type 1 Hereditary Angioedema - Type 2 HAE

Locations

ADARx Clinical Site — Litchfield Park, Arizona, United States
ADARx Clinical Site — Little Rock, Arkansas, United States
ADARx Clinical Site — San Diego, California, United States
ADARx Clinical Site — Walnut Creek, California, United States
ADARx Clinical Site — Orlando, Florida, United States
ADARx Clinical Site — Chevy Chase, Maryland, United States
ADARx Clinical Site — Wheaton, Maryland, United States
ADARx Clinical Site — Detroit, Michigan, United States
ADARx Clinical Site — St Louis, Missouri, United States
ADARx Clinical Site — Las Vegas, Nevada, United States
ADARx Clinical Site — New York, New York, United States
ADARx Clinical Site — Cincinnati, Ohio, United States
ADARx Clinical Site — Columbus, Ohio, United States
ADARx Clinical Site — Toledo, Ohio, United States
ADARx Clinical Site — Hershey, Pennsylvania, United States
ADARx Clinical Site — Capital Federal, Buenos Aires, Argentina
ADARx Clinical Site — Buenos Aires, Buenos Aires F.D., Argentina
ADARx Clinical Site — Adelaide, South Australia, Australia
ADARx Clinical Site — Vienna, Austria
ADARx Clinical Site — Edegem, Antwerpen, Belgium
ADARx Clinical Site — Sofia, Bulgaria
ADARx Clinical Site — Edmonton, Alberta, Canada
ADARx Clinical Site — Ottawa, Ontario, Canada
ADARx Clinical Site — Montreal, Quebec, Canada
ADARx Clinical Site — Beijing, China
ADARx Clinical Site — Harbin, China
ADARx Clinical Site — Zhengzhou, China
ADARx Clinical Site — Split, Croatia
ADARx Clinical Site — Zagreb, Croatia
ADARx Clinical Site — Hradec Králové, Czechia
ADARx Clinical Site — Prague, Czechia
ADARx Clinical Site — Nice, Alpes-Maritimes, France
ADARx Clinical Site — Tours, Indre-et-Loire, France
ADARx Clinical Site — Montpellier, France
ADARx Clinical Site — Paris, France
ADARx Clinical Site — Tübingen, Baden-Wurttemberg, Germany
ADARx Clinical Site — Hong Kong, Hong Kong
ADARx Clinical Site — Budapest, Hungary
ADARx Clinical Site — Ashkelon, Israel
ADARx Clinical Site — Tel Aviv, Israel
ADARx Clinical Site — Lodz, Poland
ADARx Clinical Site — Barcelona, Spain
ADARx Clinical Site — Madrid, Spain
ADARx Clinical Site — Taichung, Taiwan
ADARx Clinical Site — Cambridge, United Kingdom
ADARx Clinical Site — Cardiff, United Kingdom
ADARx Clinical Site — London, United Kingdom
ADARx Clinical Site — Southampton, United Kingdom

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment